Saito H, Goldsmith G, Waldmann R
Blood. 1976 Dec;48(6):941-7.
Fitzgerald factor (high molecular weight kininogen) is an agent in normal human plasma that corrects the impaired in vitro surface-mediated plasma reactions of blood coagulation, fibrinolysis, and kinin generation observed in Fitzgerald trait plasma. To assess the possible pathophysiologic role of Fitzgerald factor, its titer was measured by a functional clot-promoting assay. Mean +/- SD in 42 normal adults was 0.99+/-0.25 units/ml, one unit being the activity in 1 ml of normal pooled plasma. No difference in titer was noted between normal men and women, during pregnancy, or after physical exercise. Fitzgerald factor activity was significantly reduced in the plasmas of eight patients with advanced hepatic cirrhosis (0.40+/-0.09 units/ml) and of ten patients with disseminated intravascular coagulation (0.60+/-0.30 units/ml), but was normal in plasmas of patients with other congenital clotting factor deficiencies, nephrotic syndrome, rheumatoid arthritis, systemic lupus erythematosus, or sarcoidosis, or under treatment with warfarin. The plasmas of 21 mammalian species tested appeared to contain Fitzgerald factor activity, but those of two avian, two repitilian, and one amphibian species did not correct the coagulant defect in Fitzgerald trait plasmas.
菲茨杰拉德因子(高分子量激肽原)是正常人血浆中的一种物质,它能纠正菲茨杰拉德性状血浆中观察到的体外表面介导的血浆凝血、纤维蛋白溶解和激肽生成受损反应。为了评估菲茨杰拉德因子可能的病理生理作用,通过功能性促凝试验测量了其滴度。42名正常成年人的平均值±标准差为0.99±0.25单位/毫升,1个单位是1毫升正常混合血浆中的活性。正常男性和女性之间、怀孕期间或体育锻炼后,滴度没有差异。在8例晚期肝硬化患者的血浆中(0.40±0.09单位/毫升)和10例弥散性血管内凝血患者的血浆中(0.60±0.30单位/毫升),菲茨杰拉德因子活性显著降低,但在其他先天性凝血因子缺乏症、肾病综合征、类风湿性关节炎、系统性红斑狼疮或结节病患者的血浆中,或接受华法林治疗的患者血浆中,其活性正常。所测试的21种哺乳动物的血浆似乎含有菲茨杰拉德因子活性,但两种鸟类、两种爬行动物和一种两栖动物的血浆不能纠正菲茨杰拉德性状血浆中的凝血缺陷。